---
title: "Tenax Therapeutics agrees to $25 million private placement"
url: "https://aibio.space/news/tenax-therapeutics-agrees-25-million-private-placement-rtw-investments/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-06"
section: "Financings"
tickers: "NASDAQ:TENX"
source: "https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/tenx_ex991.htm"
summary: "RTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials."
---

By the aibio.space news desk.

Sources

- [Tenax Therapeutics, Inc. 8-K (2025-03-06)](https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/tenx_ex991.htm)

[TENX](https://aibio.space/companies/tenax-therapeutics/)

2025-03-06

# Tenax Therapeutics agrees to $25 million private placement with RTW Investments

Tickers [TENX](https://aibio.space/companies/tenax-therapeutics/)

RTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.

## Key facts

- **Company**: Tenax Therapeutics, Inc. (NASDAQ: TENX)

- **News type**: Financings

- **Primary source**: [Tenax Therapeutics, Inc. 8-K (2025-03-06)](https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/tenx_ex991.htm)

*Stock prices on an electronic board. CC0, via rawpixel. The picture shows the field, not the companies named.*

Tenax Therapeutics, Inc. said on March 5, 2025 that it signed a securities purchase agreement for a private placement with RTW Investments. The deal is expected to bring total gross proceeds of about $25 million, before placement agent fees and other expenses.

RTW is to buy 378,346 shares of common stock at $6.04 per share. It is also to buy pre-funded warrants to purchase 3,760,726 shares at $6.03 each. The pre-funded warrants have an exercise price of $0.01, can be exercised at any time after issuance and do not expire. A pre-funded warrant is paid for almost in full up front, leaving only a small exercise price.

The private placement was expected to close on March 5, 2025, subject to customary closing conditions. Leerink Partners is lead placement agent. Guggenheim Securities and William Blair are joint placement agents.

Tenax plans to use the net proceeds to advance its ongoing and planned Phase 3 clinical trials, and for working capital, capital expenditures and other general corporate purposes. The company develops cardiopulmonary therapies.

The securities are being sold under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered. Tenax agreed to file a registration statement for the resale of the shares, including those underlying the pre-funded warrants, no later than 45 days after closing.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

TENX

Tenax Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/tenax-therapeutics-agrees-25-million-private-placement-rtw-investments/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tenax Therapeutics agrees to $25 million private placement", 2025-03-06, https://aibio.space/news/tenax-therapeutics-agrees-25-million-private-placement-rtw-investments/